CL2013002828A1 - Anticuerpo o fragmento de union especifico para la proteina del oncogen de wilms (wt1) unido a hla-a2; acido nucleico; vector de expresion; celula para la expresion del anticuerpo; metodo para la deteccion de wt1; composicion farmaceutica; metodo para matar celula wt1+; kit para la deteccion wt1; uso para fabricar un medicamento - Google Patents

Anticuerpo o fragmento de union especifico para la proteina del oncogen de wilms (wt1) unido a hla-a2; acido nucleico; vector de expresion; celula para la expresion del anticuerpo; metodo para la deteccion de wt1; composicion farmaceutica; metodo para matar celula wt1+; kit para la deteccion wt1; uso para fabricar un medicamento

Info

Publication number
CL2013002828A1
CL2013002828A1 CL2013002828A CL2013002828A CL2013002828A1 CL 2013002828 A1 CL2013002828 A1 CL 2013002828A1 CL 2013002828 A CL2013002828 A CL 2013002828A CL 2013002828 A CL2013002828 A CL 2013002828A CL 2013002828 A1 CL2013002828 A1 CL 2013002828A1
Authority
CL
Chile
Prior art keywords
cell
detection
antibody
expression
hla
Prior art date
Application number
CL2013002828A
Other languages
English (en)
Inventor
David A Scheinberg
Tao Dao
Cheng Liu
Su Yan
Original Assignee
Memorial Sloan Kettering Cancer Center
Eureka Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46229910&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013002828(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center, Eureka Therapeutics Inc filed Critical Memorial Sloan Kettering Cancer Center
Publication of CL2013002828A1 publication Critical patent/CL2013002828A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
CL2013002828A 2011-04-01 2013-10-01 Anticuerpo o fragmento de union especifico para la proteina del oncogen de wilms (wt1) unido a hla-a2; acido nucleico; vector de expresion; celula para la expresion del anticuerpo; metodo para la deteccion de wt1; composicion farmaceutica; metodo para matar celula wt1+; kit para la deteccion wt1; uso para fabricar un medicamento CL2013002828A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161470635P 2011-04-01 2011-04-01
US201161491392P 2011-05-31 2011-05-31

Publications (1)

Publication Number Publication Date
CL2013002828A1 true CL2013002828A1 (es) 2014-07-04

Family

ID=46229910

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013002828A CL2013002828A1 (es) 2011-04-01 2013-10-01 Anticuerpo o fragmento de union especifico para la proteina del oncogen de wilms (wt1) unido a hla-a2; acido nucleico; vector de expresion; celula para la expresion del anticuerpo; metodo para la deteccion de wt1; composicion farmaceutica; metodo para matar celula wt1+; kit para la deteccion wt1; uso para fabricar un medicamento

Country Status (22)

Country Link
US (5) US9074000B2 (es)
EP (2) EP2694553B1 (es)
JP (2) JP6082997B2 (es)
KR (1) KR20140033029A (es)
CN (2) CN106632677B (es)
AP (1) AP2013007142A0 (es)
AU (2) AU2012236068A1 (es)
CA (1) CA2831336C (es)
CL (1) CL2013002828A1 (es)
CO (1) CO6900116A2 (es)
CU (1) CU20130130A7 (es)
DO (1) DOP2013000219A (es)
EA (1) EA201391449A1 (es)
ES (2) ES2651510T3 (es)
GT (1) GT201300233A (es)
MX (1) MX2013011363A (es)
MY (1) MY160662A (es)
NI (1) NI201300099A (es)
PE (1) PE20141271A1 (es)
SG (1) SG193956A1 (es)
WO (1) WO2012135854A2 (es)
ZA (1) ZA201306940B (es)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107699585A (zh) 2010-12-09 2018-02-16 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
WO2012135854A2 (en) 2011-04-01 2012-10-04 Memorial Sloan-Kettering Cancer Center Antibodies to cytosolic peptides
US10239952B2 (en) 2011-04-01 2019-03-26 Memorial Sloan Kettering Cancer Center Anti-WT1/HLA bi-specific antibody
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
CN105358576B (zh) 2013-02-20 2020-05-05 诺华股份有限公司 使用人源化抗EGFRvIII嵌合抗原受体治疗癌症
US20140271644A1 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
CA2906650A1 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Combination/adjuvant therapy for wt-1-positive disease
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CN106170297A (zh) * 2013-09-20 2016-11-30 纪念斯隆-凯特琳癌症中心 用于wt‑1‑阳性疾病的组合/辅助疗法
WO2015055318A1 (en) 2013-10-18 2015-04-23 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3066130B1 (en) * 2013-11-07 2019-05-15 Memorial Sloan-Kettering Cancer Center Anti-wt1/hla bi-specific antibody
AU2014346648A1 (en) * 2013-11-07 2016-06-23 Eureka Therapeutics, Inc. Fc-enhanced anti-WT1/HLA antibody
CN116478927A (zh) 2013-12-19 2023-07-25 诺华股份有限公司 人间皮素嵌合抗原受体及其用途
JP6793902B2 (ja) 2013-12-20 2020-12-02 ノバルティス アーゲー 調節可能キメラ抗原受容体
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
US20160152725A1 (en) * 2014-02-25 2016-06-02 Memorial Sloan-Kettering Cancer Center Antigen-binding proteins specific for hla-a2-restricted wilms tumor 1 peptide
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US11390921B2 (en) 2014-04-01 2022-07-19 Adaptive Biotechnologies Corporation Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)
EP3129470B1 (en) 2014-04-07 2021-04-07 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
US10738278B2 (en) * 2014-07-15 2020-08-11 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
KR20170037625A (ko) 2014-07-21 2017-04-04 노파르티스 아게 Cll-1 키메라 항원 수용체를 사용한 암의 치료
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
AU2015292755B2 (en) 2014-07-21 2020-11-12 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
HUE049218T2 (hu) 2014-08-19 2020-10-28 Novartis Ag Anti-CD123 kiméra antigénreceptor (CAR) rák kezelésében történõ alkalmazásra
US20180010132A1 (en) 2014-09-11 2018-01-11 Novartis Ag Inhibition of prmt5 to treat mtap-deficiency-related diseases
CA2961636A1 (en) 2014-09-17 2016-03-24 Boris ENGELS Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
EP3220926A4 (en) 2014-11-17 2018-08-08 Adicet Bio Inc. Engineered gamma delta t-cells
US10479997B2 (en) 2014-12-01 2019-11-19 Novartis Ag Compositions and methods for diagnosis and treatment of prostate cancer
JP6699013B2 (ja) * 2014-12-25 2020-05-27 国立大学法人三重大学 Ｗｔ１由来ペプチド認識抗体
EP3240803B1 (en) 2014-12-29 2021-11-24 Novartis AG Methods of making chimeric antigen receptor-expressing cells
WO2016115482A1 (en) 2015-01-16 2016-07-21 Novartis Pharma Ag Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
WO2016126608A1 (en) 2015-02-02 2016-08-11 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
WO2016154047A2 (en) * 2015-03-20 2016-09-29 Memorial Sloan-Kettering Cancer Center Monoclonal antigen-binding proteins to intracellular oncogene products
US20180208658A1 (en) * 2015-04-03 2018-07-26 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
PL3280729T3 (pl) 2015-04-08 2022-08-22 Novartis Ag Terapie cd20, terapie cd22 i terapie skojarzone komórką eksprymującą chimeryczny receptor antygenowy (car) cd19
CN108473957A (zh) 2015-04-17 2018-08-31 诺华股份有限公司 改善嵌合抗原受体表达细胞的功效和扩增的方法
US20180298068A1 (en) 2015-04-23 2018-10-18 Novartis Ag Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN106188274A (zh) * 2015-05-06 2016-12-07 广州市香雪制药股份有限公司 识别rhamm抗原短肽的t细胞受体
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
EP3307319A4 (en) * 2015-06-09 2019-05-22 Memorial Sloan Kettering Cancer Center ANTIBODIES SPECIFIC TO T-CELL RECEPTORS SPECIFIC TO EBV LATENT 2A MEMBRANE PROTEIN PRESENTED BY HUMAN HLA
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
US10829735B2 (en) 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
FR3039832A1 (fr) * 2015-08-04 2017-02-10 Univ Francois Rabelais De Tours Igg1 et leur utilisation therapeutique
US11667691B2 (en) 2015-08-07 2023-06-06 Novartis Ag Treatment of cancer using chimeric CD3 receptor proteins
PE20181322A1 (es) 2015-09-01 2018-08-14 Agenus Inc Anticuerpo anti-pd1 y sus metodos de uso
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
WO2017060201A1 (en) * 2015-10-09 2017-04-13 Immatics Biotechnologies Gmbh Anti-wt1/hla-specific antibodies
IL295398A (en) * 2015-10-23 2022-10-01 Eureka Therapeutics Inc Antibody/t-cell receptor chimera structures and their uses
MA44314A (fr) 2015-11-05 2018-09-12 Juno Therapeutics Inc Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
US11020429B2 (en) 2015-11-05 2021-06-01 Juno Therapeutics, Inc. Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
US10711282B2 (en) 2015-11-23 2020-07-14 Novartis Ag Optimized lentiviral transfer vectors and uses thereof
US11400145B2 (en) * 2015-11-27 2022-08-02 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
EP3383419B1 (en) 2015-12-03 2022-08-03 Juno Therapeutics, Inc. Compositions and methods for reducing immune responses against chimeric antigen receptors
EP3383892B1 (en) 2015-12-03 2022-12-21 Juno Therapeutics, Inc. Modified chimeric receptors and related compositions and methods
JP7082055B2 (ja) 2015-12-22 2022-06-07 ノバルティス アーゲー 抗癌治療における組み合わせ使用のためのメソテリンキメラ抗原受容体（ｃａｒ）およびｐｄ－ｌ１阻害剤に対する抗体
CA3009709A1 (en) 2015-12-30 2017-07-06 Novartis Ag Immune effector cell therapies with enhanced efficacy
KR20180104036A (ko) 2016-01-22 2018-09-19 머크 샤프 앤드 돔 코포레이션 항-응고 인자 xi 항체
GB201604492D0 (en) * 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
US11768203B2 (en) 2016-03-31 2023-09-26 University Of Southern California Highly sensitive and specific luciferase based reporter assay for antigen detection
TW201800418A (zh) 2016-04-25 2018-01-01 索倫多醫療公司 結合stat3之抗體治療劑
WO2017197347A1 (en) 2016-05-12 2017-11-16 Adicet Bio, Inc. METHODS FOR SELECTIVE EXPANSION OF γδ T-CELL POPULATIONS AND COMPOSITIONS THEREOF
MX2018014387A (es) 2016-05-27 2019-03-14 Agenus Inc Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos.
SG10202103120UA (en) 2016-06-14 2021-05-28 Merck Sharp & Dohme Anti-coagulation factor xi antibodies
MA45455A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Procédé d'identification d'épitopes peptidiques, molécules qui se lient à de tels épitopes et utilisations associées
MA45491A (fr) 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
WO2018005775A1 (en) 2016-06-29 2018-01-04 Memorial Sloan-Kettering Cancer Center Cd47 blockade enhances therapeutic activity of antibodies to low density cancer epitopes
WO2018023093A1 (en) 2016-07-29 2018-02-01 Juno Therapeutics, Inc. Immunomodulatory polypeptides and related compositions and methods
SG10201913823VA (en) 2016-10-07 2020-03-30 Novartis Ag Chimeric antigen receptors for the treatment of cancer
US10844119B2 (en) 2016-10-11 2020-11-24 Agenus Inc. Anti-LAG-3 antibodies and methods of use thereof
ES2961666T3 (es) 2016-12-03 2024-03-13 Juno Therapeutics Inc Métodos para determinar la dosificación de células CAR-T
BR112019011025A2 (pt) 2016-12-03 2019-10-08 Juno Therapeutics Inc métodos para modulação de células t car
CA3045338A1 (en) 2016-12-05 2018-06-14 Juno Therapeutics, Inc. Production of engineered cells for adoptive cell therapy
WO2018111340A1 (en) 2016-12-16 2018-06-21 Novartis Ag Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
BR112019012950A2 (pt) 2016-12-23 2019-11-26 Macrogenics Inc molécula de ligação a adam9, composição farmacêutica, uso da molécula de ligação a adam9 e método para tratar uma doença ou condição associada ou caracterizada pela expressão de adam9 em um indivíduo
CN107698681B (zh) * 2016-12-28 2020-07-07 天津天锐生物科技有限公司 一种识别hla-a2/rmfpnapyl的单域抗体
MX2019008227A (es) 2017-01-10 2020-08-17 Juno Therapeutics Inc Analisis epigenetico de terapia celular y metodos relacionados.
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
WO2018148224A1 (en) 2017-02-07 2018-08-16 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (ple) car t cell tumor targeting (ctct) agents
AU2018224856A1 (en) 2017-02-27 2019-08-29 Juno Therapeutics, Inc. Compositions, articles of manufacture and methods related to dosing in cell therapy
EP3589295A4 (en) 2017-02-28 2020-11-04 Endocyte, Inc. COMPOSITIONS AND METHODS OF T CAR LYMPHOCYTE THERAPY
BR112019018124A2 (pt) 2017-03-22 2020-04-07 Intellia Therapeutics Inc composições e métodos para imunooncologia
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
AU2018253176B2 (en) 2017-04-13 2023-02-02 Agenus Inc. Anti-CD137 antibodies and methods of use thereof
MA54103A (fr) 2017-04-14 2021-09-15 Juno Therapeutics Inc Procédés d'évaluation de la glycosylation de surface cellulaire
SG10201913656TA (en) 2017-04-26 2020-03-30 Eureka Therapeutics Inc Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
US11419895B2 (en) 2017-05-31 2022-08-23 Crage Medical Co., Limited Compositions and methods of cellular immunotherapy
MX2019014288A (es) 2017-06-02 2020-08-03 Juno Therapeutics Inc Articulos de manufactura y metodos relacionados a toxicidad asociada con terapia celular.
WO2018231958A1 (en) * 2017-06-13 2018-12-20 Adaptive Biotechnologies Corp. Determining wt-1 specific t cells and wt-1 specific t cell receptors (tcrs)
AU2017418590A1 (en) 2017-06-14 2020-01-16 Adicet Therapeutics, Inc. Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
ES2871400T3 (es) 2017-06-20 2021-10-28 Inst Nat Sante Rech Med Células inmunitarias deficientes en SUV39H1
EP3655004A2 (en) 2017-07-21 2020-05-27 Novartis AG Compositions and methods to treat cancer
EP3661528A1 (en) 2017-07-29 2020-06-10 Juno Therapeutics, Inc. Reagents for expanding cells expressing recombinant receptors
BR112020001601A2 (pt) 2017-08-09 2020-08-11 Juno Therapeutics Inc métodos e composições para preparar células geneticamente manipuladas
AU2018313950A1 (en) 2017-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for producing genetically engineered cell compositions and related compositions
EP3679370A1 (en) 2017-09-07 2020-07-15 Juno Therapeutics, Inc. Methods of identifying cellular attributes related to outcomes associated with cell therapy
CN111629749A (zh) 2017-10-18 2020-09-04 诺华股份有限公司 用于选择性蛋白质降解的组合物和方法
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
EP3700926A1 (en) 2017-10-25 2020-09-02 Novartis AG Methods of making chimeric antigen receptor-expressing cells
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
MX2020004568A (es) 2017-11-06 2020-10-05 Juno Therapeutics Inc Combinación de una terapia celular y un inhibidor de gamma secretasa.
JP2021502816A (ja) 2017-11-15 2021-02-04 アディセット バイオ， インコーポレイテッド δ３γδＴ細胞集団の選択的増殖方法及びその組成物
US20210198372A1 (en) 2017-12-01 2021-07-01 Juno Therapeutics, Inc. Methods for dosing and for modulation of genetically engineered cells
MX2020005907A (es) 2017-12-08 2020-10-19 Juno Therapeutics Inc Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
SG11202005272SA (en) 2017-12-08 2020-07-29 Juno Therapeutics Inc Process for producing a composition of engineered t cells
MX2020005906A (es) 2017-12-08 2020-10-22 Juno Therapeutics Inc Marcadores fenotipicos para terapia celular y metodos relacionados.
JP7394058B2 (ja) * 2017-12-21 2023-12-07 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
AR114001A1 (es) * 2017-12-21 2020-07-08 Hoffmann La Roche Anticuerpos que se unen a hla- a2 / wt1
JP2021512147A (ja) 2018-01-22 2021-05-13 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Ｃａｒ ｔ細胞の使用方法
KR20200128014A (ko) 2018-01-31 2020-11-11 셀진 코포레이션 입양 세포 요법 및 체크포인트 억제제를 이용한 병용 요법
EP3752601A4 (en) 2018-02-15 2022-03-23 Memorial Sloan-Kettering Cancer Center ANTI-FOXP3 DRUG COMPOSITIONS AND METHODS OF USE FOR ADOPTIVE CELL THERAPY
CN112585276A (zh) 2018-04-05 2021-03-30 朱诺治疗学股份有限公司 产生表达重组受体的细胞的方法和相关组合物
EP3784688A2 (en) 2018-04-26 2021-03-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
US20210123016A1 (en) 2018-05-02 2021-04-29 Novartis Ag Regulators of human pluripotent stem cells and uses thereof
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
CN108676098A (zh) * 2018-05-29 2018-10-19 段海峰 靶向wt1的嵌合抗原受体t细胞及其应用
EP3802825A1 (en) 2018-06-08 2021-04-14 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
TW202016139A (zh) 2018-06-13 2020-05-01 瑞士商諾華公司 Bcma 嵌合抗原受體及其用途
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CA3107383A1 (en) 2018-07-23 2020-01-30 Magenta Therapeutics, Inc. Use of anti-cd5 antibody drug conjugate (adc) in allogeneic cell therapy
CA3108698A1 (en) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Methods for assessing integrated nucleic acids
EP3833742A2 (en) 2018-08-09 2021-06-16 Juno Therapeutics, Inc. Processes for generating engineered cells and compositions thereof
CA3111789A1 (en) 2018-09-11 2020-03-19 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
IT201800009282A1 (it) * 2018-10-09 2020-04-09 Metis Prec Medicine Sb Srl Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi
BR112021008133A2 (pt) 2018-10-31 2021-10-05 Juno Therapeutics Gmbh Métodos para seleção e estimulação de células e aparelhos para os mesmos
KR20210117260A (ko) 2018-11-30 2021-09-28 주노 쎄러퓨티크스 인코퍼레이티드 입양 세포 요법을 사용한 치료방법
SG11202105860QA (en) 2018-12-03 2021-07-29 Adicet Bio Inc Methods for selective in vivo expansion of gamma delta t-cell populations and compositions thereof
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
CA3123519A1 (en) 2019-02-15 2020-08-20 Novartis Ag Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2021009763A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina -2,6-diona y usos de los mismos.
BR112021021200A2 (pt) 2019-05-01 2021-12-21 Juno Therapeutics Inc Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
MX2021013219A (es) 2019-05-01 2022-02-17 Juno Therapeutics Inc Celulas que expresan un receptor recombinante de un locus de tgfbr2 modificado, polinucleotidos relacionados y metodos.
MX2021015317A (es) 2019-06-12 2022-03-11 Juno Therapeutics Inc Terapia de combinacion de una terapia citotoxica mediada por celulas y un inhibidor de una proteina de la familia bcl2 de prosupervivencia.
JP2022542102A (ja) 2019-07-23 2022-09-29 ムネモ・セラピューティクス Ｓｕｖ３９ｈ１欠損免疫細胞
EP4017527A1 (en) 2019-08-22 2022-06-29 Juno Therapeutics, Inc. Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods
AU2020335928A1 (en) 2019-08-30 2022-02-17 Agenus Inc. Anti-CD96 antibodies and methods of use thereof
TW202134285A (zh) 2019-11-26 2021-09-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
KR20210067120A (ko) * 2019-11-29 2021-06-08 주식회사 대웅제약 Cobll1 단백질 특이 항체 또는 이의 항원 결합 단편, 및 이의 용도
JP2023507190A (ja) 2019-12-20 2023-02-21 ノバルティス アーゲー 増殖性疾患を治療するための抗ＴＧＦβ抗体及びチェックポイント阻害薬の使用
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
WO2021174198A1 (en) * 2020-02-28 2021-09-02 The Brigham And Women's Hospital, Inc. Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
EP4150640A1 (en) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Methods of identifying features associated with clinical response and uses thereof
CN116096862A (zh) 2020-06-11 2023-05-09 诺华股份有限公司 Zbtb32抑制剂及其用途
WO2021260528A1 (en) 2020-06-23 2021-12-30 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
CN116234558A (zh) 2020-06-26 2023-06-06 朱诺治疗学有限公司 条件性地表达重组受体的工程化t细胞、相关多核苷酸和方法
WO2022023576A1 (en) 2020-07-30 2022-02-03 Institut Curie Immune cells defective for socs1
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
KR20230090367A (ko) 2020-11-04 2023-06-21 주노 쎄러퓨티크스 인코퍼레이티드 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
WO2022133030A1 (en) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Combination therapy of a cell therapy and a bcl2 inhibitor
WO2022144025A1 (zh) * 2021-01-04 2022-07-07 上海翰森生物医药科技有限公司 一种抗erbb3受体的抗体或其抗原结合片段及其医药用途
US20240168012A1 (en) 2021-03-22 2024-05-23 Juno Therapeutics, Inc. Methods of determining potency of a therapeutic cell composition
JP2024511420A (ja) 2021-03-22 2024-03-13 ジュノー セラピューティクス インコーポレイテッド ウイルスベクター粒子の効力を評価する方法
AU2022246593A1 (en) 2021-03-29 2023-10-12 Juno Therapeutics, Inc. Methods for dosing and treatment with a combination of a checkpoint inhibitor therapy and a car t cell therapy
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022229853A1 (en) 2021-04-27 2022-11-03 Novartis Ag Viral vector production system
WO2022238386A1 (en) 2021-05-10 2022-11-17 Institut Curie Methods for the treatment of cancer, inflammatory diseases and autoimmune diseases
WO2022248602A1 (en) 2021-05-25 2022-12-01 Institut Curie Myeloid cells overexpressing bcl2
WO2023126458A1 (en) 2021-12-28 2023-07-06 Mnemo Therapeutics Immune cells with inactivated suv39h1 and modified tcr
WO2023139269A1 (en) 2022-01-21 2023-07-27 Mnemo Therapeutics Modulation of suv39h1 expression by rnas
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
CN114539412B (zh) * 2022-02-24 2023-09-29 广西医科大学 抗hla-a2/wt1复合物的单域抗体及其制备方法与应用
WO2023187024A1 (en) 2022-03-31 2023-10-05 Institut Curie Modified rela protein for inducing interferon expression and engineered immune cells with improved interferon expression
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
EP4279085A1 (en) 2022-05-20 2023-11-22 Mnemo Therapeutics Compositions and methods for treating a refractory or relapsed cancer or a chronic infectious disease
WO2024062138A1 (en) 2022-09-23 2024-03-28 Mnemo Therapeutics Immune cells comprising a modified suv39h1 gene
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
WO2024088383A1 (en) * 2022-10-28 2024-05-02 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-wt1/hla antibodies and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4663283A (en) 1980-03-24 1987-05-05 Genentech, Inc. Method of altering double-stranded DNA
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
US5726288A (en) * 1989-11-13 1998-03-10 Massachusetts Institute Of Technology Localization and characterization of the Wilms' tumor gene
KR100262838B1 (ko) * 1996-04-16 2003-03-15 기시모토 다다미쓰 고형암세포및조직이형성의검출방법,및골수이식및말초혈간세포이식용조직의검사방법
MXPA01003344A (es) * 1998-09-30 2004-04-21 Corixa Corp Composiciones y metodos para inmunoterapia especifica de wt1.
WO2003075846A2 (en) 2002-03-08 2003-09-18 Sloan-Kettering Institute For Cancer Research Uses of monoclonal antibody 8h9
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
US6992176B2 (en) * 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
EP1485075A4 (en) * 2002-02-20 2006-04-26 Dyax Corp MHC-PEPTIDE COMPLEX BINDING LIGANDS
JP4480580B2 (ja) * 2002-09-20 2010-06-16 株式会社癌免疫研究所 Ｗｔ１置換型ペプチド
US7595379B2 (en) 2003-05-30 2009-09-29 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
CN101384716B (zh) 2006-02-22 2013-03-13 株式会社癌免疫研究所 Hla-a*3303限制性wt1肽和包含此肽的药物组合物
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
WO2008081701A1 (ja) * 2006-12-28 2008-07-10 International Institute Of Cancer Immunology, Inc. Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物
EP2144935A2 (en) 2007-03-29 2010-01-20 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
WO2009091826A2 (en) 2008-01-14 2009-07-23 The Board Of Regents Of The University Of Texas System Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
WO2009108372A2 (en) * 2008-02-27 2009-09-03 Receptor Logic, Inc. Antibodies as t cell receptor mimics, methods of production and uses thereof
JP5356388B2 (ja) 2008-07-25 2013-12-04 電気化学工業株式会社 ヒアルロン酸の製造方法
KR20110084196A (ko) 2008-09-26 2011-07-21 유레카 쎄라퓨틱스, 인코포레이티드 다양한 글리코실화 패턴을 가진 세포계 및 단백질
KR101944557B1 (ko) 2011-02-11 2019-01-30 메모리얼 슬로안 케터링 캔서 센터 에이치엘에이 제한된, 펩타이드­특이성 항원 결합 단백질
WO2012135854A2 (en) * 2011-04-01 2012-10-04 Memorial Sloan-Kettering Cancer Center Antibodies to cytosolic peptides
US20160369006A1 (en) * 2011-04-01 2016-12-22 Memorial Sloan-Kettering Cancer Center Fc-ENHANCED ANTI-WT1/HLA ANTIBODY
US10239952B2 (en) * 2011-04-01 2019-03-26 Memorial Sloan Kettering Cancer Center Anti-WT1/HLA bi-specific antibody

Also Published As

Publication number Publication date
AU2017203511A1 (en) 2017-06-15
EA201391449A1 (ru) 2014-03-31
KR20140033029A (ko) 2014-03-17
CN106632677A (zh) 2017-05-10
EP3323833A1 (en) 2018-05-23
NZ617008A (en) 2016-02-26
ES2651510T3 (es) 2018-01-26
CN106632677B (zh) 2021-10-26
EP2694553B1 (en) 2017-10-11
CA2831336A1 (en) 2012-10-04
MX2013011363A (es) 2014-04-25
PE20141271A1 (es) 2014-10-08
AP2013007142A0 (en) 2013-09-30
CU20130130A7 (es) 2014-08-28
JP6082997B2 (ja) 2017-02-22
ZA201306940B (en) 2014-05-28
GT201300233A (es) 2015-08-04
AU2012236068A1 (en) 2013-10-17
CN103619882B (zh) 2016-10-19
CU24151B1 (es) 2016-02-29
MY160662A (en) 2017-03-15
EP2694553A2 (en) 2014-02-12
CN103619882A (zh) 2014-03-05
US9540448B2 (en) 2017-01-10
US10040865B2 (en) 2018-08-07
US9074000B2 (en) 2015-07-07
JP2014512812A (ja) 2014-05-29
NI201300099A (es) 2014-01-07
US20210163624A1 (en) 2021-06-03
US20190144563A1 (en) 2019-05-16
US20150259436A1 (en) 2015-09-17
WO2012135854A3 (en) 2013-03-14
US20170088630A1 (en) 2017-03-30
DOP2013000219A (es) 2014-02-28
AU2017203511B2 (en) 2019-07-11
JP2016026209A (ja) 2016-02-12
EP3323833B1 (en) 2019-12-04
WO2012135854A2 (en) 2012-10-04
US10858444B2 (en) 2020-12-08
SG193956A1 (en) 2013-11-29
CO6900116A2 (es) 2014-03-20
ES2785081T3 (es) 2020-10-05
CA2831336C (en) 2019-10-01
US20140294841A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
CL2013002828A1 (es) Anticuerpo o fragmento de union especifico para la proteina del oncogen de wilms (wt1) unido a hla-a2; acido nucleico; vector de expresion; celula para la expresion del anticuerpo; metodo para la deteccion de wt1; composicion farmaceutica; metodo para matar celula wt1+; kit para la deteccion wt1; uso para fabricar un medicamento
FR23C1032I1 (fr) Protéines de liaison à bcma (cd269/tnfrsf17)
CY1121934T1 (el) Αντισωματα anti-fcrn
AR089528A1 (es) Dominio variable dual de inmunoglobulinas y sus usos
CL2013000566A1 (es) Proteina de union a antigeno que une her3; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2014000631A1 (es) Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
CL2013000074A1 (es) Proteina de union con capacidad de unir un par de antigenos; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; conjugado que comprende dicha proteina de union; y sus usos.
CL2014000699A1 (es) Proteina de union al antigeno cd27l; acido nucleico que la codifica; vector de expresion; celula huesped recombinante; composicion que la comprende; su uso para tratar cancer, trastornos autoinmunitarios o inflamatorios; y metodo para elaborar un conjugado anticuerpo cd27l-farmaco.
CY1121964T1 (el) Αντισωματα εναντιον toy csf-1r
SG11201403450VA (en) Artificial nucleic acid molecules for improved protein or peptide expression
CL2013003043A1 (es) Anticuerpos de un único dominio variable dab que se unen a cd40 humano; ácido nucleico que codifica dicho anticuerpo; vector y célula huésped que lo comprenden; composición farmacéutica; uso de dichos anticuerpos para tratar enfermedad inmune.
CO6690759A2 (es) Anticuerpos, fragmentos de unión o derivados de los mismos que se unen específicamente a la proteína 4-1 bb
CL2013001831A1 (es) Proteina de enlace multivalente y multiespecifica que une a il-1 alfa y beta; conjugado que la comprende; acido nucleico que la codifica; vector; celula huesped; metodo de produccion; composicion farmaceutica que la comprende; y sus usos.
MX2015008446A (es) Composiciones de proteinas de union multivalentes.
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
CL2011002756A1 (es) Anticuerpo que se enlaza a la proteina del complemento c3b humana o de cinomolgo; composicion farmaceutica, acido nucleico, vector y celula huesped que comprenden dicho anticuerpo; uso para tratar degeneracion macular relacionada con la edad.
BR112014000263A2 (pt) anticorpo isolado ou fragmento de ligação de antígeno do mesmo, molécula de ácido nucleico, e, composição farmacêutica
CL2014001254A1 (es) Molécula de unión biespecífica para bcma y cd3; secuencia de ácido nucleico que la codifica; vector ; célula; composición farmacéutica que comprende a la molécula de unión; uso para tratar enfermedades relacionadas a transtornos de células plasmáticas, trastornos de células b correlacionados con la expresión de bcma y enfermedades autoinmunes.
BR112014008694A2 (pt) moléculas de ácido nucleico policistrônico recombinante
MX2017001403A (es) Constructo de anticuerpo de cadena individual biespecifico con distribucion mejorada de tejido.
AR079551A1 (es) Anticuerpos anti-her3 y usos de los mismos
HK1215602A1 (zh) 通過單分子操作來檢測 修飾和蛋白結合的方法
EA201491644A1 (ru) Фармацевтические композиции
BR112013021134A8 (pt) Anticorpo isolado que se liga especificamente a ptk7 humano, seu uso, composição farmacêutica que o compreende, e ácido nucleico
BR122020002402B8 (pt) Proteína de ligação de antígeno isolada recombinante que liga il-23, composição farmacêutica, molécula de ácido nucleico isolada recombinante, vetor recombinante, célula hospedeira recombinante, métodos de confecção da referida proteína de ligação e uso da mesma